

MEDICINOVA INC  
Form 8-K  
December 30, 2013

**UNITED STATES**  
**SECURITIES AND EXCHANGE COMMISSION**  
**Washington, D.C. 20549**

**FORM 8-K**

**CURRENT REPORT**

**Pursuant to Section 13 or 15(d)**

**of the Securities Exchange Act of 1934**

**Date of Report (Date of earliest event reported): December 28, 2013**

**MEDICINOVA, INC.**

**(Exact name of registrant as specified in its charter)**

**Delaware**  
**(State or other jurisdiction**

**of incorporation)**

**001-33185**  
**(Commission**

**File Number)**  
**4275 Executive Square, Suite 650**

**33-0927979**  
**(IRS Employer**

**Identification No.)**

Edgar Filing: MEDICINOVA INC - Form 8-K

**La Jolla, CA 92037**

**(Address of principal executive offices) (Zip Code)**

**Registrant's telephone number, including area code: (858) 373-1500**

**Not Applicable**

**(Former name or former address, if changed since last report)**

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- .. Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- .. Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- .. Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- .. Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

**Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.**

On December 28, 2013, Mr. Tatsuo Izumi resigned as a member of the Board of Directors of MediciNova, Inc. (the Company ), with immediate effect. Mr. Izumi s resignation was not in connection with any known disagreement with the Company on any matter.

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

**MEDICINOVA, INC.**

Dated: December 30, 2013

By: /s/ Yuichi Iwaki  
Yuichi Iwaki, M.D., Ph.D.  
President, Chief Executive Officer and  
Acting Chief Financial Officer